+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Microbiome Therapeutics Market: Focus on Drugs, Pipeline Analysis, Funding Scenario, Therapeutic Application, 10 Countries Data, and Competitive Landscape – Analysis and Forecast, 2019-2029

  • ID: 4850833
  • Report
  • October 2019
  • Region: Global
  • 193 Pages
  • BIS Research
1 of 5
Global Human Microbiome Therapeutics Market to Grow at a CAGR of 33.00% from 2019-2029

FEATURED COMPANIES

  • 4D Pharma plc
  • Ferring Pharmaceuticals
  • Immuron Limited
  • Naked Biome
  • Quorum Innovations
  • Sanofi S.A.
  • MORE

Key Questions Answered in this Report:

  • What are the key features of human microbiome therapeutics which makes them a better choice for the treatment of chronic and non-communicable disease?
  • What is the industry structure of the human microbiome therapeutics market?
  • How did the human microbiome therapeutics market evolve and what is its scope in the future?
  • What are the key development strategies which are implemented by the key players to maintain and capture market share?
  • What are the major market drivers, challenges, and opportunities in the global human microbiome therapeutics market?
  • What are the current leading companies dominating the global human microbiome therapeutics market?
  • What are the regulations pertaining to the global human microbiome therapeutics market?
  • What are the initiatives implemented by different government bodies to reduce the incidence of disease and increase the adoption of human microbiome therapeutics product?
  • What was the market value of the leading segments and sub-segments of the global human microbiome therapeutics market?
  • How is each segment of the global human microbiome therapeutics market expected to grow during the forecast period and what is the revenue expected to be generated by each of the segments by the end of 2029?
  • Which region carries the potential for the significant expansion of key companies for human microbiome therapeutics market?
  • Which products are anticipated to be launched and generate revenue in the forecast period 2019-2029?

Global Human Microbiome Therapeutics Market Forecast, 2019-2029

Human Microbiome Therapeutics Industry Analysis projects the market to grow at a significant CAGR of 33.00% during the forecast period 2019-2029. The human microbiome therapeutics market generated $309.9 million in revenue in 2018, in terms of value.

The human microbiome therapeutics growth has been primarily attributed to the major drivers in this market such as increasing prevalence and growing incidence of chronic diseases, growing investments and initiatives in the field of microbiome therapeutics, treatment options with minimal or no side effects, availability of private and government funding, and others. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include product launches, and increasing mergers and acquisitions among the industry players. However, there are significant challenges that are restraining the market growth. These challenges include exorbitant cost is required for the clinical trials procedure and stringent regulatory guidelines for the product development and commercialization of the products.

Expert Quote

“With the elucidation of its causative role in cardiometabolic disease and atherosclerosis, the human gut microbiome holds promises as a reservoir of novel potential therapeutic targets as well as novel therapeutic agents, paving a new and exciting avenue in cardiovascular drug discovery and other areas.”

Scope of the Market Intelligence on Human Microbiome Therapeutics Market

The human microbiome therapeutics market research provides a holistic view of the global market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products for different therapeutic applications in human microbiome therapeutics. In addition, the study also includes exhaustive information on expected commercial launches of the product in the forecast period, perception on the new product launches, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segments, and company, as well as other vital information with respect to global human microbiome therapeutics market.

Market Segmentation

The human microbiome therapeutics market is segmented into three categories, namely, product (by Phases), by disease, and by region.

The product segment includes the segmentation on the basis of different phases of clinical trials, and the disease segment includes, gastrointestinal and infectious diseases, oncology and autoimmune diseases, skin diseases, and neurological diseases.

The region segment is further segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World.

Key Companies in the Global Human Microbiome Therapeutics Market

The key manufacturers who have been contributing significantly to the human microbiome therapeutics market include 4D Pharma plc, Immuron Limited, Sanofi SA., Seres Therapeutics Inc., Synthetic Biologics, Taisho Pharmaceutical, Ritter Pharmaceuticals, AOBiome, Finch Therapeutics, Rebiotix, Inc. (Subsidiary of Ferring Pharmaceutical), Maat Pharma, Ox Thera, Quorum Innovations, Vedanta Biosciences, Whole Biome, and Naked Biome among others.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma plc
  • Ferring Pharmaceuticals
  • Immuron Limited
  • Naked Biome
  • Quorum Innovations
  • Sanofi S.A.
  • MORE

Executive Summary

1 Market Overview
1.1 Global Human Microbiome Therapeutics Market
1.1.1 Overview
1.1.2 Global Market Scenario
1.1.3 Market Dynamics
1.2 Product Mapping

2 Scope of the Work
2.1 Overview: Report Scope
2.2 Segmentation of the Global Human Microbiome Therapeutics Market
2.3 Assumptions and Limitations
2.4 Key Questions Answered in the Report
2.5 Base Year and Forecast Period

3 Research Methodology
3.1 Overview: Report Methodology

4 Industry Analysis
4.1 Regulatory Scenario
4.2 Regulatory Designations
4.3 Regulatory requirements for Live Biotherapeutic Products (LBPs)
4.4 Patent Analysis

5 Competitive Landscape
5.1 Overview
5.2 Key Developments and Strategies
5.2.1 Collaborations and Partnerships
5.2.2 Mergers and Acquisitions
5.2.3 Business Expansions
5.3 Market Share Analysis
5.4 Funding Scenario
5.5 Government Initiatives

6 Global Human Microbiome Therapeutics Market (by Development Phase)
6.1 Overview
6.2 Commercialized Drugs
6.3 Drugs in Phase 4
6.4 Drugs in Phase 3

7 Global Human Microbiome Therapeutics Market (by Indication)
7.1 Overview
7.2 Gastrointestinal and Infectious Diseases
7.3 Oncology and Autoimmune Diseases
7.4 Skin Diseases
7.5 Others

8 Global Human Microbiome Therapeutics Market (by Region)
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 U.S.
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 France
8.3.3 Sweden
8.3.4 Germany
8.3.5 U.K.
8.3.6 Rest-of-Europe
8.4 Asia-Pacific
8.4.1 Overview
8.4.2 Japan
8.4.3 Australia
8.4.4 China
8.4.5 India
8.4.6 Rest-of-Asia-Pacific
8.5 Rest-of-the-World
8.5.1 Overview
8.5.2 Middle East and Africa
8.5.3 Latin America

9 Company Profiles
9.1 Overview
9.2 4D Pharma plc
9.2.1 Company Overview
9.2.2 Role of 4D Pharma plc in the Global Human Microbiome Therapeutics Market
9.2.3 Financials
9.2.4 SWOT Analysis
9.3 AOBiome
9.3.1 Company Overview
9.3.2 Role of AOBiome in the Global Human Microbiome Therapeutics Market
9.3.3 SWOT Analysis
9.4 Finch Therapeutics
9.4.1 Company Overview
9.4.2 Role of Finch Therapeutics in the Global Human Microbiome Therapeutics Market
9.4.3 SWOT Analysis
9.5 Ferring Pharmaceuticals
9.5.1 Company Overview
9.5.2 Rebiotix Inc. (Subsidiary of Ferring Pharmaceuticals): Company Overview
9.5.3 Role of Rebiotix Inc. in the Global Human Microbiome Therapeutics Market
9.5.4 SWOT Analysis
9.6 Immuron Limited
9.6.1 Company Overview
9.6.2 Role of Immuron in the Global Human Microbiome Therapeutics Market
9.6.3 Financials
9.6.4 SWOT Analysis
9.7 MaaT Pharma
9.7.1 Company Overview
9.7.2 Role of MaaT Pharma in the Global Human Microbiome Therapeutics Market
9.7.3 SWOT Analysis
9.8 Naked Biome
9.8.1 Company Overview
9.8.2 Role of Naked Biome in Human Microbiome Therapeutics Market
9.8.3 SWOT Analysis
9.9 OxThera AB
9.9.1 Company Overview
9.9.2 Role of OxThera AB in the Global Human Microbiome Therapeutics Market
9.9.3 SWOT Analysis
9.10 Quorum Innovations
9.10.1 Company Overview
9.10.2 Role of Quorum Innovations, LLC in Human Microbiome Therapeutics Market
9.10.3 SWOT Analysis
9.11 Ritter Pharmaceuticals
9.11.1 Company Overview
9.11.2 Role of Ritter Pharmaceuticals in the Global Human Microbiome Therapeutics Market
9.11.3 Financials
9.11.4 SWOT Analysis
9.12 Sanofi S.A.
9.12.1 Company Overview
9.12.2 Role of Sanofi S.A. in the Global Human Microbiome Therapeutics Market
9.12.3 Financials
9.12.3.1 Key Insights About the Financial Health of the Company
9.12.4 SWOT Analysis
9.13 Seres Therapeutics, Inc.
9.13.1 Company Overview
9.13.2 Role of Seres Therapeutics, Inc. in the Global Human Microbiome Therapeutics Market
9.13.3 Financials
9.13.3.1 Key Insights About Financial Health of the Company
9.13.4 SWOT Analysis
9.14 Synthetic Biologics, Inc.
9.14.1 Company Overview
9.14.2 Role of Synthetic Biologics, Inc. in the Global Human Microbiome Therapeutics Market
9.14.3 Financials
9.14.4 SWOT Analysis
9.15 Taisho Pharmaceutical
9.15.1 Company Overview
9.15.2 Biofermin Pharmaceutical Co. Ltd. (Subsidiary of Taisho Pharmaceutical) Company Overview
9.15.3 Role of Taisho Pharmaceutical in Global Human Microbiome Therapeutics Market
9.15.4 Financial
9.15.4.1 Key Insights about the Financial Health of the Company
9.15.5 SWOT Analysis
9.16 Vedanta Biosciences, Inc.
9.16.1 Company Overview
9.16.2 Role of Vedanta Biosciences, Inc. in the Global Human Microbiome Therapeutics Market
9.16.3 SWOT Analysis
9.17 Whole Biome Inc.
9.17.1 Company Overview
9.17.2 Role of Whole Biome Inc. in the Global Human Microbiome Therapeutics Market
9.17.3 SWOT Analysis

List of Tables
Table 1.1: Product Mapping Matrix by Company (Development Phase)
Table 1.2: No. of Products by Developmental Phase
Table 1.3: No. of Products by Indications
Table 4.1: Regulatory Authorities/Associations/Consortiums of the Global Human Microbiome Therapeutics Market
Table 5.1: Ranking of Key Potential Players (2020-2029)
Table 5.2: Funding Scenario
Table 5.3: Government Initiatives in the Human Microbiome Therapeutics
Table 6.1: Global Human Microbiome Therapeutics Market (by Development Phase), 2017-2029
Table 6.2: Commercialized Products, 2017 and 2018
Table 6.3: Products in Phase 4, 2018
Table 6.4: Products in Phase 3, 2018
Table 7.1: Global Human Microbiome Therapeutics Market (by Indication), 2017-2029
Table 8.1: EU Funding of Microbiome Research Under FP7 and H2020

List of Figures
Figure 1: Antibiotic Resistance (%) in OECD Countries, 2014
Figure 2: Global Human Microbiome Modulators Market Snapshot
Figure 3: Global Human Microbiome Therapeutics, 2018-2029
Figure 4: Global Human Microbiome Therapeutics, 2018-2029 (Three Scenarios)
Figure 5: Market Drivers and Challenges of Global Human Microbiome Therapeutics Market
Figure 6: Share of Key Developments and Strategies, January 2016-August 2019
Figure 7: Pipeline Analysis
Figure 8: Global Human Microbiome Therapeutics Market (by Indication), 2023 and 2029
Figure 9: Global Human Microbiome Therapeutics Market (by Region), 2018
Figure 1.1: Evolution of Human Microbiome Modulators
Figure 1.2: Mechanisms of Action of Human Microbiome Therapeutic Drugs
Figure 1.3: Number of Drugs in Active Development, 2011-2017
Figure 1.4: Global Human Microbiome Therapeutics Market, 2018-2029
Figure 1.5: Global Human Microbiome Therapeutics, 2018-2029 (Three Scenario)
Figure 1.6: Drivers and Challenges of Global Human Microbiome Therapeutics Market
Figure 2.1: Global Human Microbiome Therapeutics Market Segmentation
Figure 3.1: Global Human Microbiome Therapeutics Market Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-up Approach (Segment-wise Analysis)
Figure 3.6: Assumptions and Limitations
Figure 4.1: Chemistry, manufacturing, and control (CMC) information of LBPs by FDA
Figure 4.2: Patent Landscape of Human Microbiome Therapeutics Market
Figure 5.1: Competitive Landscape (January 2016-August 2019)
Figure 5.2: Share of Key Developments and Strategies, January 2016-August 2019
Figure 5.3: Collaboration and Partnership (by Company), January 2016 and August 2019
Figure 5.4: Merger and Acquisition (by Company), January 2016 and August 2019
Figure 5.5: Business Expansion (by Company), January 2016 and August 2019
Figure 5.6: Market Share Analysis of Global Human Microbiome Therapeutics Market, 2017 and 2018
Figure 6.1: Global Human Microbiome Therapeutics Market, 2017-2029
Figure 6.2: Global Human Microbiome Therapeutics Market (by Commercialized Drug), 2017-2029
Figure 6.3: Global Human Microbiome Therapeutics Market (by Phase 4 Drugs), 2021-2029
Figure 6.4: Global Human Microbiome Therapeutics Market (by Phase 3 Drug), 2023-2029
Figure 7.1: Number of Pipeline Candidates for Gastrointestinal and Infectious Disease Indications
Figure 7.2: Global Human Microbiome Therapeutics Market (by Gastrointestinal and Infectious Disease),
Figure 7.3: Number of Pipeline Candidates for Oncology and Autoimmune Diseases
Figure 7.4: Global Human Microbiome Therapeutics Market (by Oncology and Autoimmune Disease),2021-2029
Figure 7.5: Number of Pipeline Candidates for Gastrointestinal and Infectious Disease Indications
Figure 7.6: Global Human Microbiome Therapeutics Market (by Skin Diseases), 2023-2029
Figure 7.7: Global Human Microbiome Therapeutics Market (by Other Diseases), 2023-2029
Figure 8.1: Global Human Microbiome Therapeutics Market (by Region), 2018
Figure 8.2: North America: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.3: North America: Market Dynamics
Figure 8.4: North America: Human Microbiome Therapeutics Market (by Country), 2018 and 2029
Figure 8.5: U.S.: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.6: Canada: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.7: Europe: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.8: Europe: Market Dynamics
Figure 8.9: Europe: Human Microbiome Therapeutic Market (by Country), 2018 and 2029
Figure 8.10: France: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.11: Sweden: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.12: Germany: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.13: U.K.: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.14: Rest-of-Europe: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.15: Asia-Pacific: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.16: Asia-Pacific: Market Dynamics
Figure 8.17: Asia-Pacific: Human Microbiome Therapeutics Market (by Country), 2018 and 2029
Figure 8.18: Japan: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.19: Australia: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.20: China: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.21: India: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.22: Rest-of-Asia-Pacific: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.23: Rest-of-the-World: Human Microbiome Therapeutics Market, 2018-2029
Figure 8.24: Rest-of-the-World: Market Dynamics
Figure 8.25: Rest-of-the-World: Human Microbiome Therapeutics Market (by Region), 2018 and 2029
Figure 9.1: Total Number of Companies Profiled
Figure 9.2: 4D Pharma plc: Overall Product Portfolio
Figure 9.3: 4D Pharma plc.: Overall Financials, 2016-2018
Figure 9.4: 4D Pharma plc: SWOT Analysis
Figure 9.5: AOBiome.: Overall Product Portfolio
Figure 9.6: AOBiome: SWOT Analysis
Figure 9.7: Finch Therapeutics: Overall Product Portfolio
Figure 9.8: Finch Therapeutics: SWOT Analysis
Figure 9.9: Rebiotix Inc.: Overall Product Portfolio
Figure 9.10: Rebiotix Inc.: SWOT Analysis
Figure 9.11: Immuron: Overall Product Portfolio
Figure 9.12: Immuron: Overall Financials, 2016-2018
Figure 9.13: Immuron: Research and Development Expenditure, 2016-2018
Figure 9.14: Immuron: SWOT Analysis
Figure 9.15: MaaT Pharma.: Overall Product Portfolio
Figure 9.16: MaaT Pharma: SWOT Analysis
Figure 9.17: Naked Biome: Overall Product Portfolio
Figure 9.18: Naked Biome: SWOT Analysis
Figure 9.19: OxThera AB: Overall Product Portfolio
Figure 9.20: OxThera AB: SWOT Analysis
Figure 9.21: Quorum Innovations, LLC: Overall Product Portfolio
Figure 9.22: Quorum Innovations, LLC: SWOT Analysis
Figure 9.23: Ritter Pharmaceuticals: Overall Product Portfolio
Figure 9.24: Ritter Pharmaceuticals: Overall Financials, 2016-2018
Figure 9.25: Ritter Pharmaceuticals: SWOT Analysis
Figure 9.26: Sanofi S.A.: Overall Product Portfolio
Figure 9.27: Sanofi S.A.: Overall Financials, 2016-2018
Figure 9.28: Sanofi S.A.: Revenue (by Segment), 2016-2018
Figure 9.29: Sanofi S.A.: Region Revenue (by Consumer Health Segment), 2016-2018
Figure 9.30: Sanofi S.A.: Consumer Healthcare Revenue (by Sub-Segment), 2016-2018
Figure 9.31: Sanofi S.A.: Research and Development Expenditure, 2016-2018
Figure 9.32: Sanofi S.A.: SWOT Analysis
Figure 9.33: Seres Therapeutics, Inc.: Overall Product Portfolio
Figure 9.34: Seres Therapeutics, Inc.: Overall Financials, 2016-2018
Figure 9.35: Seres Therapeutics Inc.: R&D Expenditure, 2016-2018
Figure 9.36: Seres Therapeutics Inc.: SWOT Analysis
Figure 9.37: Synthetic Biologics, Inc.: Overall Product Portfolio
Figure 9.38: Synthetic Biologics, Inc.: Overall Financials, 2016-2018
Figure 9.39: Synthetic Biologics, Inc.: SWOT Analysis
Figure 9.40: Taisho Pharmaceutical Co., Ltd.: Overall Product Portfolio
Figure 9.41: Taisho Pharmaceutical Co., Ltd.: Overall Financials, 2016-2018
Figure 9.42: Taisho Pharmaceutical Co., Ltd. (by Segment), 2016-2018
Figure 9.43: Taisho Pharmaceutical Co., Ltd.: Biofermin Sales, 2016-2018
Figure 9.44: Taisho Pharmaceutical Co., Ltd. (by Region), 2016-2018
Figure 9.45: Taisho Pharmaceutical Co., Ltd.: R&D Expenditure, 2016-2018
Figure 9.46: Taisho Pharmaceutical Co., Ltd.: SWOT Analysis
Figure 9.47: Vedanta Biosciences, Inc.: Overall Product Portfolio
Figure 9.48: Vedanta Biosciences, Inc.: SWOT Analysis
Figure 9.49: Whole Genome Inc.: Overall Product Portfolio
Figure 9.50: Whole Biome Inc.: SWOT Analysis

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 4D Pharma plc
  • Ferring Pharmaceuticals
  • Immuron Limited
  • Naked Biome
  • Quorum Innovations
  • Sanofi S.A.
  • MORE

One of the undermined factors for the rising global disease burden is antimicrobial resistance (AMR). Mainly a natural phenomenon, antimicrobial resistance is triggered by the excess usage of antibiotics for the treatment of diseases with microbial origins. A complex issue of global concern, AMR is majorly driven by human action and perverse incentives. AMR is further accelerated by global trade and travel.

With AMR posing a significant burden on healthcare systems and national budgets worldwide, the world has now progressed into the ‘post-antibiotic era’. Common infections have again been rendered as fatal and are now demanding precise therapeutic modules. Thus, the governing bodies of different nations are restructuring their policies and norms in order to help the companies in reducing the cost and make advanced healthcare solutions which are accessible to a wide range of the population. The advent of precision medicine - a patient-centric treatment approach, is perceived to be promising in driving a paradigm shift in the healthcare industry, facilitating the elimination of uncertainty pertaining to trial and error method of medications, and consequently eliminating unnecessary healthcare spending. Thus, considerable acceptance has been received by the precision medicine approach in the healthcare industry.

The year 2003 marks the completion of the Human Genome Project, a 13-year, $3 billion collaborative effort for the sequencing and mapping of the complete human genome. This project further enabled scientists to research extensively on the gene variants to specific diseases and develop targeted therapeutics, depending on the genetic profile of an individual. The extension of the precision medicine approach through the Human Genome Project (HGP), the Human Microbiome Project (HMP) was implemented to acquire the ‘complete’ scope of the human body for precision care. The microbiota, constituting the entire population of the microbes residing within and on the human body, have been realized to be higher in population than the human cells – having an approximate ratio of 10:1, respectively. The microbiome, referred to as the genomic content of the microbiota, has now become an area of increasing focus to understand the function and role of the microbial components in disease incidence. NCDs, being an area direly in need of immediate therapeutic interventions, have naturally become a prevalent scope for human microbiome therapeutics.

According to this report, the global human microbiome therapeutics market was valued $309.9 million and is anticipated to grow at a CAGR of 33% in the forecast period 2019-2029.

Note: Product cover images may vary from those shown
5 of 5
  • 4D Pharma plc
  • AOBiome
  • Finch Therapeutics
  • Ferring Pharmaceuticals
  • Immuron Limited
  • MaaT Pharma
  • Naked Biome
  • OxThera AB
  • Quorum Innovations
  • Ritter Pharmaceuticals
  • Sanofi S.A.
  • Seres Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • Taisho Pharmaceutical
  • Vedanta Biosciences, Inc.
  • Whole Biome Inc.
Note: Product cover images may vary from those shown
Adroll
adroll